Abbott Labs Files 8-K on Operations and Financials

Ticker: ABT · Form: 8-K · Filed: 2025-07-17T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, financials

Related Tickers: ABT

TL;DR

ABT filed an 8-K on 7/17/25 for results of ops & financials. No numbers yet.

AI Summary

Abbott Laboratories filed an 8-K on July 17, 2025, reporting on its results of operations and financial condition, and filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.

Why It Matters

This filing indicates Abbott Laboratories is providing updates on its financial performance and operational status to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — The filing is a standard disclosure of operations and financial condition without immediate negative or positive financial implications mentioned.

Key Players & Entities

FAQ

What specific financial results are being reported by Abbott Laboratories in this 8-K?

The provided text indicates the filing is for 'Results of Operations and Financial Condition' but does not specify the actual financial results or figures.

What is the date of this 8-K filing?

The date of the report is July 17, 2025.

What is the principal executive office address for Abbott Laboratories?

The address is 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is Abbott Laboratories' state of incorporation?

Abbott Laboratories is incorporated in Illinois.

From the Filing

0001628280-25-035135.txt : 20250717 0001628280-25-035135.hdr.sgml : 20250717 20250717073453 ACCESSION NUMBER: 0001628280-25-035135 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250717 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250717 DATE AS OF CHANGE: 20250717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 251128820 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20250717.htm 8-K abt-20250717 0000001800 FALSE New York Stock Exchange Chicago Stock Exchange, Inc. 0000001800 2025-07-17 2025-07-17 0000001800 exch:XCHI 2025-07-17 2025-07-17 0000001800 exch:XNYS 2025-07-17 2025-07-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 _______________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 17, 2025 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) _______________________________________________________ Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification  No.) _______________________________________________________ 100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: ( 224 ) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition On July 17, 2025, Abbott Laboratories announced its results of operations for the second quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, fair value adjustments to the contingent consideration related to busin

View on Read The Filing